Literature DB >> 74204

Evaluation of radiation therapy for bone metastases: pain relief and quality of life.

H A Gilbert, A R Kagan, H Nussbaum, A R Rao, J Satzman, P Chan, B Allen, A Forsythe.   

Abstract

The records of 158 patients irradiated for bone metastases were reviewed to evaluate the effectiveness of pain relief and to judge the effect of treatment on overall quality of life. Within 3 months 73% of the sites treated had pain relief, with 55%-65% having sustained relief up to 1 year or death. Of patients surviving more than 3 months, 63% maintained a satisfactory quality of life and were able to take care of most personal needs. The median survival of all patients was 1 year from initial treatment for bone metastasis. Radiation dose and the primary tumor site do not seem to be significant prognostic factors for initial pain relief or quality of life.

Entities:  

Mesh:

Year:  1977        PMID: 74204     DOI: 10.2214/ajr.129.6.1095

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  22 in total

1.  Role of radiotherapy in the management of bone metastases from breast cancer.

Authors:  J R Yarnold
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

2.  Solitary painful osseous metastases: correlation of imaging features with pain palliation after radiofrequency ablation--a multicenter american college of radiology imaging network study.

Authors:  Jeffrey P Guenette; Michael J Lopez; Eunhee Kim; Damian E Dupuy
Journal:  Radiology       Date:  2013-05-08       Impact factor: 11.105

Review 3.  The pathophysiology and management of spine metastasis from lung cancer.

Authors:  J S Greenberger
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

4.  Vertebroplasty in the treatment of vertebral tumors: postprocedural outcome and quality of life.

Authors:  L Alvarez; A Pérez-Higueras; D Quiñones; E Calvo; R E Rossi
Journal:  Eur Spine J       Date:  2003-03-22       Impact factor: 3.134

5.  Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases.

Authors:  W Y Lin; C P Lin; S J Yeh; B T Hsieh; Z T Tsai; G Ting; T C Yen; S J Wang; F F Knapp; M G Stabin
Journal:  Eur J Nucl Med       Date:  1997-06

6.  Palliative interventions for pain in cancer patients.

Authors:  Alda Tam; Kamran Ahrar
Journal:  Semin Intervent Radiol       Date:  2007-12       Impact factor: 1.513

7.  Clinical outcomes after percutaneous vertebroplasty for pathologic compression fractures in osteolytic metastatic spinal disease.

Authors:  Bong-Suk Lim; Ung-Kyu Chang; Sang-Min Youn
Journal:  J Korean Neurosurg Soc       Date:  2009-06-30

8.  A minimally invasive surgical treatment possibility of osteolytic vertebral collapse in multiple myeloma.

Authors:  Stefano Astolfi; Laura Scaramuzzo; Carlo A Logroscino
Journal:  Eur Spine J       Date:  2009-05-13       Impact factor: 3.134

9.  Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.

Authors:  J M de Klerk; B A Zonnenberg; A D van het Schip; A van Dijk; S H Han; J M Quirijnen; G H Blijham; P P van Rijk
Journal:  Eur J Nucl Med       Date:  1994-10

10.  Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study.

Authors:  Mehmet Halit Yilmaz; Mustafa Ozguroglu; Devrim Mert; Hande Turna; Gökhan Demir; Ibrahim Adaletli; Sila Ulus; Metin Halac; Kaya Kanberoğlu
Journal:  Med Oncol       Date:  2007-11-27       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.